Topica Pharmaceuticals, Inc.: Series B $27M

Posted in I - Series B, Q - 4Q11, R - WEST, X - Antifungal, X - Antiinfective, XX - CA

Topica Pharmaceuticals (Palo Alto, CA) a clinical-stage pharmaceutical company focused on treatments for onychomycosis, closed a $27M Series B financing. Participants include Third Rock Ventures, Prospect Venture Partners and Yasuda Enterprise Development Corporation.

Jan

2009

Lytix Biopharma, AS: Series D $10.4M

Posted in I - Series D, Q - 1Q09, R - INTERNATIONAL, X - Antibacterial, X - Antifungal, X - Antiinfective, X - Oncology

Lytix Biopharma (Norway) pre-clinical developer of lytic peptide drugs for the treatment of resistant bacterial, fungal infections and tumor progression, closed a $10.4M Series D financing.
Participants in financings have included Picasso Kapital, Såkorninvest Nord, Norinnova, Sparebanken Nord-Norge Invest, Serepta, Rekdal, Svendsen, Norinnova Invest and Taj Holding.

Dec

2008

SpePharm Holding NV: Series C $20.3M

Posted in I - Series C, Q - 3Q08, R - INTERNATIONAL, X - Antifungal, X - Mucositis

SpePharm (Netherlands) commercial-stage marketer of anti-fungal and mucositis drugs to the EU market, closed a $20.3M Series C financing. Participants included TVM Capital, Signet Healthcare Partners and Paul Capital Healthcare.

Nov

2008

Myconostica, Ltd.: Series A $9.7M

Posted in I - Series A, Q - 2Q08, R - INTERNATIONAL, X - Antifungal, X - Antiinfective

Myconostica (Manchester, England) early-stage company focused on the treatment of Pneumocystis and Aspergillus infections, closed a $9.7M Series A financing. Participants include Nexus Medical Partners, Innoven Partenaires, Medicis Ventures and Amphion Innovations.

to top of page...